Overview

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

Status:
NOT_YET_RECRUITING
Trial end date:
2027-09-13
Target enrollment:
Participant gender:
Summary
The main purpose of this Ph2a study is to evaluate the preliminary efficacy, safety and tolerability of GIA632 when administered to adult participants with moderate to severe atopic dermatitis (AD).
Phase:
PHASE2
Details
Lead Sponsor:
Novartis Pharmaceuticals